Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The MAPK pathway in melanoma.

Leslie A Fecher1, Ravi K Amaravadi, Keith T Flaherty

  • 1University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA. leslie.fecher@uphs.upenn.edu

Current Opinion in Oncology
|February 28, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026
Same author

Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Cell reports·2026
Same author

Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i>-Mutant Melanoma.

bioRxiv : the preprint server for biology·2026
Same author

Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance.

bioRxiv : the preprint server for biology·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Understanding the MAPK pathway in melanoma is crucial for developing new cancer therapies. Targeting this pathway, particularly BRAF mutations, shows promise for effective melanoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer research is increasingly focused on tumor heterogeneity and molecular profiling.
  • The MAPK pathway is frequently dysregulated in melanoma, similar to HER2/neu in breast cancer.
  • Advances in understanding melanoma genetics are driving the development of targeted therapies.

Purpose of the Study:

  • To review the current understanding of the MAPK pathway in melanoma.
  • To summarize therapeutic strategies targeting the MAPK pathway in melanoma.
  • To highlight the role of tumor profiling in advancing melanoma treatment.

Main Methods:

  • Review of current scientific literature on melanoma biology and MAPK pathway.
  • Analysis of genetic abnormalities and their correlation with clinical presentation.

Related Experiment Videos

  • Evaluation of therapeutic agents targeting the MAPK pathway.

    • Main Results:

    • Melanomas exhibit distinct molecular and genetic abnormalities linked to sun exposure and body site.
    • BRAF or NRAS mutations are the most common MAPK pathway abnormalities in melanoma.
    • Targeted inhibitors of BRAF and other MAPK pathway members show potential efficacy.

    Conclusions:

    • Tumor profiling has significantly advanced melanoma research.
    • The MAPK pathway is a key target for melanoma therapeutics.
    • Combinatorial therapies targeting multiple disrupted pathways are likely to be most successful.